Page 9 - Meissa Vaccines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Jul 19, 2021 By Gail Dutton Martin Moore, Ph.D., CEO and co-founder of Meissa Vaccines, pictured above.  Meissa Vaccines’ intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting. The caveat is that the data is from preclinical, non-human primate studies. The data – also published on bioRxiv – indicates that the MV-014-212 vaccine-induced mucosal (nasal IgA) antibodies in the upper respiratory tract and systemic (serum neutralizing and binding IgG antibodies) in African green monkeys and provided protection when challenged by the wild-type SARS-CoV-2 virus.

South africaUnited statesUnited kingdomSouth africanMartin moore meissaMartin mooreMariana tioniWorld health organizationAmerican society of virologyMeissa vaccinesAmerican societyஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்மார்டின் மூர்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்அமெரிக்கன் சமூகம் ஆஃப் வைராலஜி